AZD0530 Difumarate

Phase 2Small molecule

AZD0530 Difumarate is one of 4 small molecule programs targeting Fibrodysplasia Ossificans Progressiva. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fibrodysplasia Ossificans ProgressivaActive, not recruiting

Fibrodysplasia Ossificans ProgressivaPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Fibrodysplasia Ossificans Progressiva

#DrugCompanyPhaseTrials

Versed

CConrado Roberto Hoffmann Filho

Garetosmab

3 3

INCB000928

Incyte

Phase 2

1 4

AZD0530 Difumarate

AAmsterdam UMC, location VUmc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Fibrodysplasia Ossificans Progressiva

NCT04307953

Clinical

Trials by Indication[1]

Fibrodysplasia Ossificans Progressiva1 trial

Saracatinib Trial TO Prevent FOP

Active, not recruiting·AAmsterdam UMC, location VUmc·Phase 2·NCT04307953·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD0530 Difumarate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD0530 Difumarate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD0530 Difumarate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amsterdam UMC, location VUmc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAmsterdam UMC, location VUmc

AZD0530 Difumarate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Fibrodysplasia Ossificans Progressiva1 trial

References

Drug Info

Quick Facts

Related News